Saisheng Pharmaceutical: signed a new drug technology transfer contract with a total transaction amount of 20 million yuan.

Sai Sheng Pharmaceutical announced that the company has signed a "New Drug Technology Transfer Contract" with its affiliated company, Huada Protein. Huada Protein will transfer the technology related to its NeoAB33 new drug project to the company, with a total transaction amount of 20 million yuan. The chairman and general manager of the company, Ma Liu, chief engineer Kong Shuangquan, and director Yin Changcheng hold director or executive positions at Huada Protein, making this transaction a related party transaction. After obtaining the relevant technology, the company will accelerate the construction of the protein/antibody drug platform, improve the full process capabilities from molecular design to cell strain construction, expand the pipeline reserve in the cardiovascular and cerebrovascular field, promote differentiation in the submarkets, and accelerate the transformation of research and development results.